ImmuPharma (IMM/L) the specialist discovery and development pharmaceutical company has announced its interim results for the six months ended 30th June, 2008.
- first patients dosed in Phase IIb trial of the lead asset for lupus, IPP-201101, during the period under review with subsequent ongoing progress being made and headline efficacy data expected later in the year.
- The company has successfully obtained LUPUZORTM trademark for IPP-201101, the lead asset for lupus.
- There has been encouraging pre-clinical data from the new portfolio candidate, IPP-204106 for multiple forms of cancer.
- £2.7m was raised in a share placing from UK and Swiss institutional investors.
Commenting on the progress to date and the outlook for ImmuPharma, Dimitri Dimitriou, Chief Executive Officer, said:
"The first half of 2008 has been an exciting time for ImmuPharma with the addition of IPP-204106 for the treatment of cancer, the first patients being dosed with LUPUZOR* and ongoing progress being made in a Phase IIb trial that is anticipated to report headline efficacy data later in the year, and a successful share placement raising £2.7m. The Company continues to develop its assets and discussions with potential partners."